{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:09:31Z","timestamp":1761498571213,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.beha.2021.101257","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T12:27:28Z","timestamp":1613392048000},"page":"101257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Which novel agents will have a clinically meaningful impact in AML at diagnosis?"],"prefix":"10.1016","volume":"34","author":[{"given":"Alexander E.","family":"Perl","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2021.101257_bib1","first-page":"485","article-title":"Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia","volume":"57","author":"Yates","year":"1973","journal-title":"Cancer Chemother Rep"},{"issue":"22","key":"10.1016\/j.beha.2021.101257_bib2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.901.901","article-title":"Swog S1203: a randomized phase III study of standard cytarabine plus daunorubicin (7+3) therapy versus idarubicin with high dose cytarabine (IA) with or without Vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML)","volume":"128","author":"Garcia-Manero","year":"2016","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2021.101257_bib3","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1182\/blood-2015-01-623447","article-title":"A randomized comparison of daunorubicin 90 mg\/m2 vs 60 mg\/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients","volume":"125","author":"Burnett","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2021.101257_bib4","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","article-title":"Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study","volume":"117","author":"Ohtake","year":"2011","journal-title":"Blood"},{"issue":"6293","key":"10.1016\/j.beha.2021.101257_bib5","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/347558a0","article-title":"The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus","volume":"347","author":"de The","year":"1990","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.beha.2021.101257_bib6","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1073\/pnas.052011299","article-title":"UBE1L is a retinoid target that triggers PML\/RARalpha degradation and apoptosis in acute promyelocytic leukemia","volume":"99","author":"Kitareewan","year":"2002","journal-title":"Proc Natl Acad Sci U. S. A."},{"issue":"2","key":"10.1016\/j.beha.2021.101257_bib7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ccr.2005.01.005","article-title":"A sumoylation site in PML\/RARA is essential for leukemic transformation","volume":"7","author":"Zhu","year":"2005","journal-title":"Canc Cell"},{"issue":"2","key":"10.1016\/j.beha.2021.101257_bib8","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.beha.2021.101257_bib9","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Canc Discov"},{"issue":"2","key":"10.1016\/j.beha.2021.101257_bib10","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.beha.2021.101257_bib11","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.beha.2021.101257_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.beha.2021.101257_bib13","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.beha.2021.101257_bib14","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2021.101257_bib15","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101257_bib16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1182\/blood-2020-134736","article-title":"Results of venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with acute myeloid leukemia with IDH 1\/2 mutations","volume":"136","author":"Pollyea","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2021.101257_bib17","doi-asserted-by":"crossref","first-page":"e724","DOI":"10.1016\/S2352-3026(20)30210-6","article-title":"10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial","volume":"7","author":"DiNardo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101257_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood-2020-142687","article-title":"Quizartinib with decitabine +\/- venetoclax is highly active in patients (pts) with FLT3-ITD mutated (mut) acute myeloid leukemia (AML): clinical report and signaling cytof profiling from a phase IB\/II trial","volume":"136","author":"Yilmaz","year":"2020","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.beha.2021.101257_bib19","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.7500","article-title":"Phase Ib\/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +\/- azacitidine in IDH1-mutated hematologic malignancies","volume":"38","author":"Lachowiez","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2021.101257_bib20","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.beha.2021.101257_bib21","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","article-title":"Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia","volume":"3","author":"Winters","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.beha.2021.101257_bib22","article-title":"Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: a propensity score matched analysis stratified by risk of treatment-related mortality","author":"Maiti","year":"2020","journal-title":"Am J Hematol"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101257_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-136120","article-title":"Venetoclax and azacitidine for newly diagnosed non-elderly adult patients with acute myeloid leukemia and adverse risk features","volume":"136","author":"Gutman","year":"2020","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.beha.2021.101257_bib24","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-127251","article-title":"Outcomes after stem cell transplant in older patients with acute myeloid leukemia treated with venetoclax-based therapies","volume":"134","author":"Pratz","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101257_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-134300","article-title":"Interim analysis of the phase 1b\/2 study of the BCL-2 inhibitor venetoclax in combination with standard intensive AML induction\/consolidation therapy with FLAG-IDA in patients with newly diagnosed or relapsed\/refractory AML","volume":"136","author":"Lachowiez","year":"2020","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.beha.2021.101257_bib26","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.beha.2021.101257_bib27","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.beha.2021.101257_bib28","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2006-04-015743","article-title":"Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors","volume":"108","author":"Levis","year":"2006","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.beha.2021.101257_bib29","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1200\/JCO.2013.48.8783","article-title":"Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status","volume":"31","author":"Cortes","year":"2013","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"10.1016\/j.beha.2021.101257_bib30","article-title":"Crenolanib besylate, a type I pan-FLT3 inhibitor, demonstrates clinical activity in multiply relapsed FLT3-ITD and D835 AML","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.beha.2021.101257_bib31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S1470-2045(17)30416-3","article-title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","volume":"18","author":"Perl","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.beha.2021.101257_bib32","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-110975","article-title":"Updated results from a phase 1 study of gilteritinib in combination with induction and consolidation chemotherapy in subjects with newly diagnosed acute myeloid leukemia (AML)","volume":"132","author":"Pratz","year":"2018","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2021.101257_bib33","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.beha.2021.101257_bib34","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med."},{"issue":"11","key":"10.1016\/j.beha.2021.101257_bib36","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.beha.2021.101257_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Canc Cell"},{"issue":"5","key":"10.1016\/j.beha.2021.101257_bib38","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a first-in-class therapy targeting acute myeloid leukemia harboring oncogenic IDH2 mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Canc Discov"},{"issue":"4","key":"10.1016\/j.beha.2021.101257_bib39","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1021\/acsmedchemlett.7b00421","article-title":"Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers","volume":"9","author":"Popovici-Muller","year":"2018","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"10.1016\/j.beha.2021.101257_bib40","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.beha.2021.101257_bib41","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.beha.2021.101257_bib42","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood-2012-01-402545","article-title":"Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML","volume":"120","author":"Sexauer","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.beha.2021.101257_bib43","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/bloodadvances.2018029496","article-title":"Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia","volume":"3","author":"McMahon","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.beha.2021.101257_bib44","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.beha.2021.101257_bib45","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1\/2 study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.beha.2021.101257_bib46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood-2013-01-478172","article-title":"FLT3 inhibitor-induced neutrophilic dermatosis","volume":"122","author":"Fathi","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.beha.2021.101257_bib47","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1001\/jamadermatol.2015.6121","article-title":"FLT3 inhibitor-associated neutrophilic dermatoses","volume":"152","author":"Varadarajan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.beha.2021.101257_bib48","article-title":"The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed\/refractory acute myeloid leukemia","author":"Altman","year":"2020","journal-title":"Canc Med"},{"issue":"8","key":"10.1016\/j.beha.2021.101257_bib49","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","article-title":"Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 inhibition in acute myeloid leukemia","volume":"9","author":"McMahon","year":"2019","journal-title":"Canc Discov"},{"issue":"9","key":"10.1016\/j.beha.2021.101257_bib50","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1182\/bloodadvances.2020001503","article-title":"Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML","volume":"4","author":"Choe","year":"2020","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101257_bib51","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2020-139705","article-title":"Efficacy and safety of venetoclax in combination with gilteritinib for relapsed\/refractory FLT3-mutated acute myeloid leukemia in the expansion cohort of a phase 1b study","volume":"136","author":"Daver","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101257_bib52","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-110976","volume":"132","author":"Esteve","year":"2018","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.beha.2021.101257_bib53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2020-137568","article-title":"Next-generation sequencing (NGS)-Based measurable residual disease (MRD) monitoring in acute myeloid leukemia with FLT3 internal tandem duplication (FLT3-ITD+ AML) treated with additional midostaurin","volume":"136","author":"Herzig","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101257_bib54","doi-asserted-by":"crossref","first-page":"623a","DOI":"10.1182\/blood.V122.21.623.623","article-title":"Results of a phase 1 study of quizartinib (AC220, ASP2689) in combination with induction and consolidation chemotherapy in younger patients with newly diagnosed acute myeloid leukemia","volume":"122","author":"Altman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101257_bib55","article-title":"Low relapse rate in younger patients \u2264 60 Years old with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) treated with crenolanib and cytarabine\/anthracycline chemotherapy","volume":"130","author":"Wang","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.beha.2021.101257_bib56","article-title":"Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study","author":"Stein","year":"2020","journal-title":"Blood"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692621000220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:05:58Z","timestamp":1761498358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692621000220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1521692621000220"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2021.101257","relation":{},"ISSN":["1521-6926"],"issn-type":[{"type":"print","value":"1521-6926"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which novel agents will have a clinically meaningful impact in AML at diagnosis?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2021.101257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101257"}}